Page last updated: 2024-12-07

2',6'-pipecoloxylidide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2',6'-Pipecoloxylidide (also known as PPC) is an organic compound that has been studied for its potential as an analgesic. It acts as a non-narcotic analgesic and is similar in structure to lidocaine. Research has explored its synthesis through various methods, including the reaction of 2,6-dimethylaniline with piperidine. Studies have investigated its effects on pain perception and its potential as an alternative to traditional analgesics. However, there are concerns regarding its toxicity, and further research is needed to determine its safety and efficacy for clinical use.'

2',6'-pipecoloxylidide: major metabolite of bupivacaine; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID115282
CHEBI ID173673
SCHEMBL ID3261012
MeSH IDM0084176

Synonyms (61)

Synonym
AC-2123
15883-20-2
CHEBI:173673
2,6-pipecoloxylidide
n-(2,6-dimethylphenyl)piperidine-2-carboxamide
desbutylbupivacaine
n-desbutylbupivacaine
brn 0206391
2',6'-pipecoloxylidide
2',6'-pipecolylxylidine
piperidine-2-carboxylic acid 2,6-dimethylanilide
n-(2,6-dimethylphenyl)-2-piperidinecarboxamide
debutylbupivacaine
demethylmepivacaine
2-piperidinecarboxamide, n-(2,6-dimethylphenyl)-
AKOS000188838
FT-0666276
n-(2,6-dimethylphenyl)piperidine-2-carboxamide;n-(2',6'-dimethylphenl)-2-piperidine carboxamide
A18251
unii-nf8rn1v7vm
nf8rn1v7vm ,
4-22-00-00098 (beilstein handbook reference)
n-(2',6'-dimethylphenyl)-2-piperidinecarboxamide
FT-0649311
FT-0649312
FS-2754
n-(2',6'-dimethylphenl)-2-piperidine carboxamide
AM20050057
SILRCGDPZGQJOQ-UHFFFAOYSA-N
piperidine-2-carboxylic acid (2,6-dimethyl-phenyl)-amide
bupivacaine metabolite ppx
(rs)-n-(2,6-dimethylphenyl)piperidine-2-carboxamide
bupivacaine hydrochloride impurity b [ep impurity]
mepivacaine hydrochloride impurity b [ep impurity]
2',6'-pipecoloxylidide, (+/-)-
(2rs)-n-(2,6-dimethylphenyl)piperidine-2-carboxamide
n-(2',6'-dimethylphenyl)-2-piperidine carboxamide
SY021146
mfcd01701244
SY018608
SCHEMBL3261012
DS-0343
Q-100191
n-desbutyl bupivacaine
D4348
desbutylbupivacaine, analytical standard
mepivacaine impurity b, european pharmacopoeia (ep) reference standard
n-desbutylbupivacaine (n-desmethylmepivacaine)
n-(2`,6`-dimethylphenyl)-2-piperidinecarboxamide
2 inverted exclamation mark ,6 inverted exclamation mark -pipecolylxylidine
BCP22656
n-(2,6-dimethylphenyl)pipecolinamide
n-(2,6-dimethylphenyl)-piperidine-2-carboxylic amide
(s)-n-(2,6-dimethylphenyl)-piperidine-2-carboxylic amide
Q27284841
AKOS016842269
CS-0038135
mepivacaine impurity b
DTXSID90870436
(s)-n-(2',6'-dimethylphenyl)-2-piperidinecarboxamide
PD065488

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In this rat model, desbutylbupivacaine was about half as toxic as bupivacaine judged by cardiac parameters, and clearly less toxic to the central nervous system than bupivacaine."( Acute cardiovascular and central nervous system toxicity of bupivacaine and desbutylbupivacaine in the rat.
Heavner, JE; Rosenberg, PH, 1992
)
0.28
" In conclusion, the present study demonstrated that PPX is more toxic than expected since we found that its induced mortality was approximately three times that found for bupivacaine and its CNS toxicity was about two times that of bupivacaine."( Acute toxicity of bupivacaine metabolites in mice.
Attolini, L; Bruguerolle, B; Gantenbein, M, 1994
)
0.29

Pharmacokinetics

ExcerptReferenceRelevance
" The relationship between pharmacokinetic parameters and creatinine clearance (CL(CR)) was assessed."( Pharmacokinetics of ropivacaine in patients with chronic renal failure.
Ekstrand, A; Henriksson, J; Honkanen, E; Pere, PJ; Rosenberg, PH; Salonen, M; Sjövall, J, 2011
)
0.37
"One-compartment first-order pharmacokinetic models incorporating linear binding of ropivacaine and PPX to α(1)-acid glycoprotein were used."( Population pharmacokinetic analysis of ropivacaine and its metabolite 2',6'-pipecoloxylidide from pooled data in neonates, infants, and children.
Aarons, L; Henriksson, J; Molnár, V; Pitsiu, M; Sadler, B; Sjövall, J, 2011
)
0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amino acid amideAn amide of an amino acid formed formally by conversion of the carboxy group to a carboxamido group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (11.76)18.7374
1990's21 (61.76)18.2507
2000's7 (20.59)29.6817
2010's2 (5.88)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.58 (24.57)
Research Supply Index3.61 (2.92)
Research Growth Index4.89 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (5.88%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other32 (94.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]